

LISTING OF THE CLAIMS:

This listing of the claims will replace all prior versions, and listings, of the claims in the present application.

1-20. (cancelled.)

21. (previously presented) A method of treatment for secretory diarrhea in animals, including humans, said method comprising: administering, via the oral route of administration to a non-human animal selected from the group consisting of bovine, ovine, swine, poultry, equine, canine and feline animals or a human suffering from secretory diarrhea, a pharmaceutical composition comprising from 0.1 to 100 mg/kg/day of an aqueous soluble proanthocyanidin polymer composition isolated from a *Croton* species or a *Calophyllum* species, said aqueous soluble proanthocyanidin polymer composition being in an amount effective to treat secretory diarrhea and formulated to protect the aqueous soluble proanthocyanidin polymer composition from the stomach environment in a controlled release preparation, and a pharmaceutically acceptable carrier.

22. (previously presented) A method of treatment for secretory diarrhea in animals, including humans, said method comprising: administering, via the oral route of administration, to a non-human animal or human suffering from secretory diarrhea, a pharmaceutical composition comprising from 0.1 to 100 mg/kg/day of an aqueous soluble proanthocyanidin polymer composition isolated from a *Croton* species or from a *Calophyllum* species, said aqueous soluble proanthocyanidin polymer composition being in an amount effective to treat secretory diarrhea and coated with an enteric coating.

23. (previously presented) The method of claim 22, in which the *Croton* species is *Croton lechleri*.

24. (original) The method of claim 22, in which the enteric coating is comprised of a methacrylic acid-methacrylic acid ester copolymer with acid ionizable groups.

25. (original) The method of claim 22, in which the pharmaceutical composition is formulated as a compressed tablet.

26. (original) The method of claim 22, in which the pharmaceutical composition further comprises a lubricant.

27. (original) The method of claim 26, in which the lubricant is magnesium stearate.

28. (previously presented) The method of claim 22, in which the pharmaceutical composition is formulated as a capsule, which capsule is enteric coated.

29. (previously presented) The method of claim 28, in which the capsule contains beads, each bead comprising a core of the proanthocyanidin polymer composition and a layer of the enteric coating.

30. (previously presented) The method of claim 22, in which the secretory diarrhea is caused by a bacterium.

31. (original) The method of claim 22, in which the secretory diarrhea is caused by a non-infectious etiology.

32. (previously presented) The method of claim 31, in which the non-infectious etiology is selected from the group consisting of non-specific diarrhea, ulcerative colitis, and irritable bowel syndrome.

33. (previously presented) The method of claim 22, in which the human suffering from secretory diarrhea is an infant or a child.

34. (previously presented) The method of claim 22, in which a human is treated for HIV-Associated Chronic Diarrhea.

35. (previously presented) The method of claim 22, in which a human is treated for diarrhea caused by cholera.

36. (original) The method of claim 22, in which a non-human animal is treated for secretory diarrhea.

37. (previously presented) The method of claim 36, in which the non-human animal is selected from the group consisting of bovine, swine, ovine, poultry, equine, canine and feline animals.

38. (previously presented) The method of claim 36 in which the pharmaceutical composition is administered in animal feed.

39. (cancelled.)

40. (previously presented) The method of claim 22, in which said pharmaceutical composition comprises between 0.1 and 40 mg/kg/day of the aqueous soluble proanthocyanidin polymer composition.

41-74. (cancelled.)

75. (previously presented) The method of claim 22, in which the aqueous soluble proanthocyanidin polymer composition is directly compressible.

76. (previously presented) The method of claim 22, in which the pharmaceutical composition further comprises a pharmaceutically acceptable carrier.

APPLICANTS' INTERVIEW SUMMARY RECORD

Applicants' representative thanks Examiner Marx for the courtesy of the telephonic interviews in connection with the above-identified application. Pursuant to MPEP section 713.04, Applicants submit the following statements of the substance of telephonic interviews held between Examiner Irene Marx and Applicants' representative Margaret Brivanlou in connection with the above-identified application.

January 19, 2005

A telephonic interview between Applicants' representative Margaret Brivanlou and Examiner Marx was held on January 19, 2005. Examiner Marx indicated that deletion of the phrase "and cancers and neoplasias of the gastrointestinal tract" from claim 32 would address the stated concern. Examiner Marx also indicated that, for the claims to be in condition for allowance, Applicants should cancel claim 34, drawn to HIV-associated Chronic Diarrhea. In particular, Examiner Marx stated that she did not believe the specification enabled treatment of HIV-associated Chronic Diarrhea using the claimed method. Examiner Marx agreed that data from clinical trials could address this concern.

February 21, 2005

A telephonic interview between Applicants' representative Margaret Brivanlou and Examiner Marx was held on February 21, 2005. Examiner Marx indicated that the last after final response will be considered and an action sent as soon as possible.